Carvedilol Tablet, Film Coated
Product Images NDC 68462-164

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 68462-164). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lbl12.5mg100.jpg

Carvedilol 12.5 mg film-coated tablets label from Glenmark Pharmaceuticals Inc., USA. The label includes the product name, dosage strength of 12.5 mg, quantity of 100 tablets, designation as USP tablets for oral use, and a barcode. The label also displays regulatory information including 'Rx Only'.*

FDA Label Image

Lbl3.125mg100.jpg

Carvedilol Tablets USP 3.125 mg film-coated tablets label from Glenmark Pharmaceuticals Inc., USA. The label includes the tablet strength (3.125 mg), package size of 100 tablets, and the designation Rx Only. It also features regulatory text, a barcode, and the Glenmark logo.*

FDA Label Image

Lbl6.25mg100.jpg

Carvedilol 6.25 mg film-coated tablets packaging label, containing 100 tablets. The label includes the product name, strength, dosage form, and Glenmark Pharmaceuticals Inc., USA as the labeler. The label also displays the NDC number, a barcode, and prescription-only designation.*

FDA Label Image

Carvedilol 25mg 100tab

Carvedilol Tablets, USP 25 mg film-coated tablets carton label from Glenmark Pharmaceuticals Inc., USA. The label indicates a package size of 100 tablets, prescription use only, and includes storage and usage information along with UPC barcode and manufacturing details.*

FDA Label Image

Figure-1 (Figure 1)

A line chart comparing percent mortality over 21 months between Placebo and Carvedilol groups. The graph shows mortality increasing over time, with the Carvedilol group having a lower mortality rate than the Placebo group. A P value of 0.0014 is indicated, suggesting statistical significance.*

FDA Label Image

Figure-2 (Figure 2)

A forest plot showing hazard ratios with confidence intervals for various subgroups including sex, age, race, diabetes status, ischemic conditions, heart rate, systolic blood pressure, spironolactone use, and overall patients. The x-axis represents hazard ratio values ranging from 0.0 to 2.0, with a vertical line at 1.0 for reference.*

FDA Label Image

Figure-3 (Figure 3)

A survival analysis graph titled 'Survival Analysis for CAPRICORN (intent-to-treat)' showing percentage mortality over 24 months. The graph compares two lines representing mortality rates for placebo and Carvedilol groups, with the Carvedilol group showing lower mortality. The p-value is 0.03, indicating statistical significance.*

FDA Label Image

Figure-4 (Figure 4)

A forest plot titled 'Figure 4. Effects on Mortality for Subgroups in CAPRICORN' showing hazard ratios for various patient subgroups. The x-axis represents hazard ratios from 0.4 to 1.3, with vertical lines at 0.7, 1.0, and 1.3. Two columns of subgroup comparisons are displayed, including age, gender, timing of randomization post-MI, prior beta-blocker use, Killip classification, thrombolytic therapy, PTCA for MI, heart failure history, diuretic use, angina, hypertension, diabetes, heart rate, and systolic blood pressure. Each subgroup is marked with black circles and confidence intervals, illustrating the effect of treatment on mortality risk within these subgroups.*

FDA Label Image

Structure

Chemical structure of Carvedilol, displaying its molecular arrangement including aromatic rings, hydroxyl group, ether linkages, and amino groups as shown in the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.